









Markets
/
Stocks
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

206.785USD

-4.695-2.22%

Market hours （ET）Quotes delayed by 15 min

4.08BMarket Cap

33.72P/E TTM



Ligand Pharmaceuticals Inc

206.785

-4.695-2.22%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ligand Pharmaceuticals Inc

Currency: USD Updated: 2026-03-12

Key Insights

Ligand Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 244.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ligand Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

2 / 157

Overall Ranking

7 / 4559

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ligand Pharmaceuticals Inc Highlights

StrengthsRisks

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 104.16% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 268.09M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 34.49, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 20.48M shares, decreasing 1.52% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 4.21K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.11.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

244.500

Target Price

+15.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-12

The current financial score of Ligand Pharmaceuticals Inc is 8.73, ranking 24 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 59.67M, representing a year-over-year increase of 39.37%, while its net profit experienced a year-over-year increase of 244.06%.

Score

Industry at a Glance

Previous score

8.43

Change

0.3



Financials

7.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ligand Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-12

The current valuation score of Ligand Pharmaceuticals Inc is 7.25, ranking 84 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 34.49, which is 153.38% below the recent high of 87.38 and 1707.82% above the recent low of -554.46.

Score

Industry at a Glance

Previous score

7.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 2/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-12

The current earnings forecast score of Ligand Pharmaceuticals Inc is 8.75, ranking 7 out of 157 in the Pharmaceuticals industry. The average price target is 232.50, with a high of 275.00 and a low of 220.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

244.500

Target Price

+15.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Ligand Pharmaceuticals Inc

LGND

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-12

The current price momentum score of Ligand Pharmaceuticals Inc is 9.28, ranking 6 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 233.36 and the support level at 184.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.64

Change

-0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

4.604

Buy

RSI(14)

60.213

Neutral

STOCH(KDJ)(9,3,3)

66.781

Sell

ATR(14)

11.242

High Vlolatility

CCI(14)

73.929

Neutral

Williams %R

33.415

Buy

TRIX(12,20)

0.400

Sell

StochRSI(14)

17.733

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

211.014

Sell

MA10

207.539

Sell

MA20

197.442

Buy

MA50

196.070

Buy

MA100

195.460

Buy

MA200

169.363

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-12

The current institutional shareholding score of Ligand Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.07%, representing a quarter-over-quarter increase of 1.63%. The largest institutional shareholder is The Vanguard, holding a total of 2.07M shares, representing 10.51% of shares outstanding, with 1.12% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.63M

-1.05%

The Vanguard Group, Inc.

Star Investors

2.07M

-0.63%

Janus Henderson Investors

1.04M

-1.73%

State Street Investment Management (US)

749.36K

-0.05%

Nomura Investment Management Business Trust

751.79K

-18.86%

Fidelity Management & Research Company LLC

457.23K

+1643.63%

Chicago Capital, LLC

568.61K

-0.56%

MFS Investment Management

541.85K

+59.49%

Stephens Investment Management Group, LLC

554.54K

-8.31%

Franklin Advisers, Inc.

229.42K

+23.58%

Risk Assessment

Currency: USD Updated: 2026-03-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ligand Pharmaceuticals Inc is 7.80, ranking 34 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Ligand Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.